Highlights
- Paramagnetic rim lesions (PRLs) are independent and potent predictors of the development of clinical symptoms in individuals with radiologically isolated syndrome (RIS).
- Higher counts of PRLs correlate significantly with earlier symptom onset; in some cohorts, having 4 or more PRLs increased the risk of conversion by over 14-fold.
- The validation of PRLs as a prognostic biomarker strengthens the scientific case for recognizing ‘asymptomatic Multiple Sclerosis’ within updated diagnostic frameworks.
- Chronic active demyelination, characterized by microglia-driven iron accumulation at lesion borders, is detectable years before the first clinical attack.
Background
Radiologically isolated syndrome (RIS) describes a clinical scenario where individuals undergo magnetic resonance imaging (MRI) for reasons unrelated to multiple sclerosis (MS)—such as headache or trauma—and incidentally reveal white matter lesions (WMLs) that meet the Barkhof or McDonald criteria for dissemination in space. While RIS represents the earliest detectable stage of the MS spectrum, predicting which individuals will progress to symptomatic MS remains a significant clinical challenge. Current prognosticators, including the presence of spinal cord lesions, oligoclonal bands, and the ‘central vein sign’ (CVS), provide some clarity, but they often fail to capture the underlying pathological activity of the lesions themselves.
In recent years, advanced neuroimaging has identified paramagnetic rim lesions (PRLs) as a hallmark of chronic active (or ‘smoldering’) demyelination. Unlike traditional inactive lesions, PRLs feature a peripheral rim of iron-laden macrophages and activated microglia, indicating persistent inflammatory activity and axonal loss. While PRLs have been extensively studied in established MS as markers of disease progression and disability accumulation, their role in the asymptomatic phase (RIS) has only recently been elucidated. The emergence of evidence suggesting that these lesions can predict the transition to clinical MS marks a pivotal shift in how we approach early neuroimmunological intervention.
Key Content
Pathophysiological Basis of Paramagnetic Rim Lesions
To understand the clinical weight of PRLs, one must first appreciate their biological significance. Using 3-Tesla (3-T) or 7-T MRI susceptibility-weighted imaging, clinicians can visualize a dark ‘rim’ surrounding a WML. This rim is composed of iron-rich myeloid cells that drive a slow expansion of the lesion core. Histopathological correlates have confirmed that these rim-positive lesions are significantly more destructive than rim-negative ones, exhibiting a higher degree of axonal transection and a failure of remyelination. In the context of RIS, the presence of such lesions indicates that the ‘asymptomatic’ period is not necessarily a ‘quiescent’ period, but rather one where active neurodegeneration is already underway beneath the clinical threshold.
Synthesis of Clinical Evidence (2011–2024)
A landmark multicenter prospective cohort study (Lim et al., 2026) has provided definitive data on the prognostic value of PRLs. By following 79 individuals with RIS across three academic centers for over a decade, researchers established two distinct cohorts: a discovery cohort (DC) and a validation cohort (VC). The findings were striking in their consistency and magnitude.
Clinical Conversion Rates and Time-to-Onset
In the discovery cohort, approximately 25% of individuals with RIS developed clinical MS over a median follow-up of 6.4 years. The median time to the first clinical event was 5.2 years. In the validation cohort, the conversion rate was 21% over 4.4 years. The study utilized time-varying Cox regression to demonstrate that for every additional PRL present at baseline or accrual, the hazard of developing clinical symptoms increased significantly (HR 1.15 in DC; HR 1.51 in VC). This suggests a ‘dose-response’ relationship between the burden of chronic active inflammation and the speed of clinical manifestation.
Thresholds for Risk Stratification
The research highlighted specific thresholds that could guide clinical decision-making. In the discovery cohort, the presence of 4 or more PRLs was associated with an odds ratio (OR) of 14.64 for clinical conversion. Even more compellingly, in the validation cohort, the presence of even a single PRL was significantly associated with developing MS, with an OR of 20.90. This underscores the high specificity of PRLs; while not every RIS patient has them, those who do are at an exceptionally high risk of symptomatic disease.
The Complementary Role of the Central Vein Sign (CVS)
The study also examined the central vein sign (CVS+L), a marker of the perivenular origin of MS lesions. While most RIS patients exhibited high proportions of CVS+ lesions—confirming that the incidental findings were indeed MS-related—the PRL count proved to be a more dynamic predictor of *when* a patient would become symptomatic. This distinction is crucial: CVS helps with the ‘what’ (diagnosis), while PRL helps with the ‘when’ and ‘how fast’ (prognosis).
Expert Commentary
The findings presented by Lim et al. represent a major step toward the ‘biologization’ of MS diagnosis. For decades, the field has relied on the occurrence of a clinical attack to confirm a diagnosis. However, as seen in other chronic neurological conditions like Alzheimer’s or Parkinson’s disease, wait-and-see approaches are increasingly viewed as suboptimal. The presence of PRLs in RIS patients provides a window into the ‘smoldering’ aspect of the disease that was previously invisible.
One controversy that remains is the therapeutic implication: Should we treat asymptomatic individuals who have high PRL counts? While the ARISE and CELLO trials have already investigated the use of dimethyl fumarate and ocrelizumab in RIS, the ability to select the highest-risk patients using PRL counts could refine future trial designs. Furthermore, the inclusion of PRLs in the McDonald diagnostic criteria could allow for an earlier diagnosis of ‘asymptomatic MS,’ potentially sparing patients from the irreversible axonal loss that occurs during the first ‘official’ relapse.
However, limitations must be noted. 3-T MRI and specialized susceptibility-weighted sequences are required for accurate PRL detection, which may not be available in all clinical settings. There is also the need for standardized automated detection tools to reduce inter-rater variability in identifying these subtle rim features.
Conclusion
The transition from Radiologically Isolated Syndrome to clinical Multiple Sclerosis is no longer an unpredictable event. Paramagnetic rim lesions serve as a potent biomarker of chronic active inflammation that portends an imminent and high risk of clinical conversion. The evidence suggests that individuals with RIS harboring PRLs—particularly those with multiple such lesions—are already in the early stages of a progressive inflammatory disease. Future clinical guidelines should prioritize the assessment of PRLs to guide risk stratification, patient counseling, and the potential for early-initiation disease-modifying therapy, ultimately aiming to prevent the first clinical attack and the accumulation of long-term disability.
References
- Lim TR, Suthiphosuwan S, Gaitán MI, et al. Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome. JAMA neurology. 2026;83(3):250-258. PMID: 41587044.
- Absinta M, Sati P, Masuzzo F, et al. Association of 7-T Magnetic Resonance Imaging Signatures With Clinical Outcomes in Multiple Sclerosis. JAMA Neurology. 2019;76(3):309-319. PMID: 30556834.
- Lebrun-Frenay C, Kantarci O, Siva A, et al. Radiologically Isolated Syndrome: 10-Year Risk Estimates of a Clinical Event. Annals of Neurology. 2023;94(2):345-356. PMID: 37194632.
